Last reviewed · How we verify
efgartigimod PH20 SC in stage B — Competitive Intelligence Brief
phase 2
Biologic
Live · refreshed every 30 min
Target snapshot
efgartigimod PH20 SC in stage B (efgartigimod PH20 SC in stage B) — argenx.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| efgartigimod PH20 SC in stage B TARGET | efgartigimod PH20 SC in stage B | argenx | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- efgartigimod PH20 SC in stage B CI watch — RSS
- efgartigimod PH20 SC in stage B CI watch — Atom
- efgartigimod PH20 SC in stage B CI watch — JSON
- efgartigimod PH20 SC in stage B alone — RSS
Cite this brief
Drug Landscape (2026). efgartigimod PH20 SC in stage B — Competitive Intelligence Brief. https://druglandscape.com/ci/efgartigimod-ph20-sc-in-stage-b. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab